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Abstract
Human cancers are complex ecosystems composed of cells with distinct phenotypes, genotypes
and epigenetic states, but current models do not adequately reflect tumor composition in patients.
We used single cell RNA-seq to profile 430 cells from five primary glioblastomas, which we
found to be inherently variable in their expression of diverse transcriptional programs related to
oncogenic signaling, proliferation, complement/immune response and hypoxia. We also observed
a continuum of stemness-related expression states that enabled us to identify putative regulators of
stemness in vivo. Finally, we show that established glioblastoma subtype classifiers are variably
expressed across individual cells within a tumor and demonstrate the potential prognostic
implications of such intratumoral heterogeneity. Thus, we reveal previously unappreciated
heterogeneity in diverse regulatory programs central to glioblastoma biology, prognosis, and
therapy.
Tumor heterogeneity poses a major challenge to cancer diagnosis and treatment. It can
manifest as variability between tumors, wherein different stages, genetic lesions or
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expression programs are associated with distinct outcomes or therapeutic responses (1–3).
Alternatively, cells from the same tumor may harbor different mutations or exhibit distinct
phenotypic or epigenetic states (4–7). Such intratumoral heterogeneity is increasingly
appreciated as a determinant of treatment failure and disease recurrence (8).
Glioblastoma is an archetypal example of a heterogeneous cancer and one of the most lethal
human malignancies (9, 10). Intratumoral heterogeneity and redundant signaling routes
likely underlie the inability of conventional and targeted therapies to achieve long-term
remissions (11–13). These tumors contain cellular niches enriched for distinct phenotypic
properties, including transient quiescence and self-renewal (14–16), adaptation to hypoxia
(17), and resistance to radiation induced DNA damage (18, 19). DNA and RNA profiles of
bulk tumors have enabled genetic and transcriptional classification of glioblastomas (20,
21). However, the relationships between different sources of intratumoral heterogeneity –
genetic, transcriptional and functional – remain obscure.
Single cell transcriptome analysis by RNA-seq (22, 23) should in principle enable functional
characterization from landmark genes and annotated gene sets, relate in vivo states to in vitro
models, inform transcriptional classifications based on bulk tumors, and even capture
genetic information for expressed transcripts. To interrogate intratumoral heterogeneity
systematically, we isolated individual cells from five freshly resected and dissociated human
glioblastomas and generated single cell full-length transcriptomes using SMART-seq (96–
192 cells/tumor, total 672 cells; Fig. 1A). Prior to sorting, the suspension was depleted for
CD45+ cells to remove inflammatory infiltrate. As a control, we also generated population
(bulk) RNA-seq profiles from the CD45-depleted tumor samples. All tumors were IDH1/2
wild type primary glioblastomas (Fig. S1) and three were EGFR amplified as determined by
routine clinical tests (Table S1). We excluded genes and cells with low coverage (24),
retaining ~6,000 genes quantified in 430 cells from five patient tumors and population
controls (Table S1). The population level controls correlated with the average of the single
cells in that tumor (Fig. S2), supporting the accuracy of the single cell data. Individual cells
from the same tumor were more correlated to each other than cells from different tumors
(Fig. S2). Nevertheless, correlations between individual cells from the same tumor showed a
broad spread (R~0.2–0.7) (Fig. S2), consistent with intratumoral heterogeneity.
Although our isolation procedures specifically targeted glioblastoma cells, we tested
whether our sampling also included normal cells. To distinguish normal from malignant, we
attempted to infer large-scale copy number alterations for each cell by averaging relative
expression levels over large genomic regions (24). This allowed us to suppress individual
gene-specific expression patterns and emphasize the signal of large-scale copy number
variations (CNVs). As a control, we included RNA-seq profiles from (bulk) normal human
brain (25). Hierarchical clustering of all single cells and normal brain samples identified
seven groups with concordant CNV profiles (Fig. 1B). The normal brain sample clustered
with 10 single cells that presumably have ‘normal’ copy number. In parallel, unsupervised
transcriptional analysis identified 9 outlier cells with increased expression of mature
oligodendrocyte genes and down-regulation of glioblastoma genes (Fig. S3,S4).
Remarkably, all nine of these expression outliers clustered with the normal brain in the CNV
analysis (Fig. 1B). The one additional ‘normal’ cell inferred from this CNV cluster
Patel et al. Page 2
Science. Author manuscript; available in PMC 2014 December 20.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
correlated with a monocytic expression signature (26) (Fig. 1B). None of the remaining 420
cells show similarity to the transcriptional programs of non-malignant brain or immune cell
types (Fig. S5) (24). While non-malignant cells are critical components of the tumor
microenvironment, the combination of dissociation methods, CD45+ depletion, flow
cytometry gating and computational filtering used in this study largely excluded non-tumor
cells.
Normalization of CNV profiles using signal from the ‘normal’ cluster revealed coherent
chromosomal aberrations in each tumor (Fig. 1C). Gain of chromosome 7 and loss of
chromosome 10, the two most common genetic alterations in glioblastoma (20), were
consistently inferred in every tumor cell. Chromosomal aberrations were relatively
consistent within tumors, with the exception that MGH31 appears to contain two genetic
clones with discordant copy number changes on chromosomes 5, 13 and 14. While this data
suggests largescale intratumoral genetic homogeneity, we recognize that heterogeneity
generated by focal alterations and point mutations will be grossly underappreciated using
this method. Nevertheless, such panoramic analysis of chromosomal landscape effectively
separated normal from malignant cells.
To interrogate global transcriptional interrelationships, we used multi-dimensional scaling to
represent the degree of similarity between the cells in the dataset (Fig. 1D, (24)). In contrast
to the chromosome-scale analysis above, we observed extensive intratumoral heterogeneity
at the transcriptional level. Although most cells grouped by tumor of origin, there were
many examples of cells from one tumor crossing into the transcriptional space of another
tumor. Moreover, the transcriptional diversity within each individual tumor was
significantly greater than that observed for the normal oligodendrocytes (Fig. S4) or for an
in vitro model of stem-like tumor propagating glioblastoma cells (GBM6, GBM8) (27, 28)
(Fig. S2).
Cell-to-cell variability is also evident in the expression and splicing patterns of signaling
molecules such as receptor tyrosine kinases (RTKs), which are important therapeutic targets
(29). Mosaic RTK amplification and redundant signaling pathways contribute to targeted
therapy resistance in glioblastoma (11, 30, 31). We found mosaic expression for EGFR,
PDGFRA, PDGFA, FGFR1, FGF1, NOTCH2, JAG1 and other surface receptors and ligands
in pathways pertinent to glioblastoma (Figs. 1E,S6,S7). Notably, the transcripts encoding
such genes are highly expressed in individual cells and in the aggregate profiles, increasing
our confidence that their absence reflects true negatives (23). Additionally, multiple EGFR
truncations and in-frame deletions have been described, including an oncogenic mutant
form, EGFRvIII, which lacks the extra-cellular domain (de2–7) and is a putative target for
immunotherapy (32). Of the three tumors with significant EGFR expression in our dataset
(MGH26, MGH30, and MGH31), MGH30 expresses EGFRvIII. By examining junction-
spanning ‘spliced’ reads at the single cell level, we identified cells expressing wild type
EGFR (7%), EGFRvIII (19%), as well as a second oncogenic variant (de4 (33); 25%) (Fig.
S8). These variants were almost mutually exclusive, with just 1–2% of cells co-expressing
wild type EGFR and EGFRvIII. Moreover, several cells lack EGFR but express other
tyrosine kinase receptors, suggesting potential alternative pathways for proliferative
signaling (Figs. 1E,S7). For example, EGFR expression is anti-correlated with PDGFRA and
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PDGFC expression in cells from MGH30 (Fig. S9). These findings suggest that
heterogeneous expression and/or mutational status of RTKs and other signaling molecules
across individual glioblastoma tumor cells may compromise therapies targeting receptor
immunogenicity or RTK signaling.
We next used hierarchical clustering and principal component analysis (PCA) to define four
meta-signatures, each comprised of multiple related clusters that coherently vary across
individual cells from a given tumor or the full dataset (24) (Fig. 2A). These four meta-
signatures were respectively enriched for genes related to cell cycle (Fig. 2B), hypoxia (Fig.
2C), complement/immune response (Fig. S10), and oligodendrocyte function (demarcating
the 9 normal oligodendrocytes). We validated the co-expression of meta-signature genes by
single cell qPCR on another 91 cells from MGH26 and 76 cells from MGH30 using primers
for 24 genes (Fig. S11). Although immune cells are an important component of the tumor
microenvironment, expression of complement and immune genes by malignant cells was
somewhat unexpected. We validated this result using two approaches. MGH29 harbors a
previously described p53 mutation, R248L (C→T) (34) (Table S1). Although coverage of
this transcript was relatively low, we identified three cells from MGH29 that clearly contain
this oncogenic mutation. All of these cells also expressed C3 and other genes from the
complement/immune module (Fig. S12). Moreover, direct examination of additional cells
scoring for the complement/immune signature confirmed chromosomal aberrations
characteristic of glioblastoma (Fig. 1C). Notably, the module may be more generally
relevant as robust co-expression of these genes was detected in multiple cell lines derived
from brain tumors in the Cancer Cell Line Encyclopedia (CCLE) (Fig. S13) (35).
Another notable feature of the module analysis is the activity of the cell cycle program in a
relatively small proportion of cells from each tumor, ranging from just 1.4% in MGH31 to
21.9% in MGH30 (Table S2, Fig. 2B). These values contrast markedly with the in vitro
glioblastoma models in which almost 100% of cells scored positively for the cell cycle
module, but are relatively consistent with Ki67+ quantifications for these tumors (Fig.
S14,S15). We investigated several markers previously linked to quiescence, including
HES1, TSC22D1, and KDM5B (36–38). Transcripts for HES1 were not well detected in our
data due to low expression, but TSC22D and KDM5B showed significantly higher
expression in non-cycling tumor cells (Fig. S16A). KDM5B, which has been implicated in
quiescence and therapeutic resistance in melanoma, was detected in 10–20% of individual
cells across all tumors and confirmed to anti-correlate with cell cycle by single cell qPCR in
MGH26 (Fig. S16B).
Clustering of genes anti-correlated to the cell cycle meta-signature also revealed a group of
12 genes (Fig. S17A), nine of which were in the hypoxia meta-signature (Fig. 2C). In fact,
these meta-signatures were diametrically opposed (Fig. S17B). Although this meta-signature
might be influenced by tissue processing procedures, hypoxia has been studied extensively
as a stimulus for angiogenesis (17) and transdifferentiation of glioblastoma stem cells into
vascular endothelium (39–41). Reordering of the cells by hypoxic module score, which was
pronounced in MGH28 and MGH31, demonstrated clear gradients in each sample (Fig. 2C),
potentially reflecting variations in the tumor microenvironment that impact oxygen tension,
blood supply or nutritional source (17, 39–41). Further studies are needed to understand the
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spatial relationships of these transcriptional niches in vivo. Thus, in vivo microenvironment
and genes linked to quiescence may affect dormant and possibly refractory compartments in
glioblastoma.
Glioblastomas likely contain a primitive subpopulation of stem-like cells (GSC) with
preferential resistance to existing therapies (16, 18). GSCs can be modeled in vitro as
spherogenic cultures that potently initiate tumors in mice (15, 27). Glioblastoma is also
postulated to contain more differentiated cells (DGCs) that can be expanded as adherent
monolayers in serum (27, 40). We established GSC and DGC cultures from three of our
tumors (MGH26, MGH28, MGH31). As expected, the GSCs exhibit a stem-like phenotype,
express the stemness marker CD133, and propagate tumors in xenotransplantation (Figs.
3A,S18). To identify in situ tumor cells with stem-like or differentiated phenotypes, we
derived a stemness signature from a consensus set of genes differentially expressed between
three respective GSC and DGC culture models (Fig. 3B).
Application of the stemness signature to the single cell transcriptional profiles revealed
stemness gradients in all five tumors (Fig. 3D). The stemness gradient is modestly anti-
correlated to the cell cycle meta-signature (Fig. 3C), consistent with the notion that stem-like
cells divide at lower overall rates (16). Notably, the stemness-differentiation axis was
occupied continuously rather than discretely, consistent with the notion that the respective in
vitro models emulate phenotypic extremes but do not capture the full spectrum of cellular
states within a primary tumor.
Genes correlated to the in vivo gradient include expected classifier genes from the in vitro
analysis, as well as additional candidates that may reflect aspects of stemness not evident in
the culture model (Fig. S19, red and blue, respectively). These include several transcription
factors (TFs), including POU3F2, NFIA and NFIB, which have been implicated in tumor
propagation, neural stem cell self-renewal and quiescence (42, 43). The in vivo stemness
gradient also significantly correlated with the average expression of target genes for these
TFs, which we predicted from ChIP-seq data (Fig. 3C). Thus, expression signatures and
regulatory circuits derived from GSC and neural stem cell models converge to a coherent
gradient of cells within primary glioblastoma, and identify TFs likely to promote stem-like
regulatory programs in vivo.
We next considered the classification scheme established by the Cancer Genome Atlas
(TCGA) (21) to distinguish four glioblastoma subtypes: proneural, neural, classical, and
mesenchymal. Although these original definitions were established from bulk tumor
profiles, we wanted to explore whether individual cells in a tumor vary in their
classification. Based on population level (bulk) expression data, the tumors in our study
scored as proneural (MGH26), classical (MGH30) or mesenchymal (MGH28, MGH29)
subtypes (Fig. S20). To examine the distribution of subtype signatures across individual
cells, we calculated subtype scores for each cell using the classifier gene sets.
All five tumors consist of heterogeneous mixtures with individual cells corresponding to
different glioblastoma subtypes (Fig. 4A,B). All tumors had some cells conforming to a
proneural subtype regardless of the dominant subtype of the tumor, whereas each of the
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other subtypes was below detection in at least one tumor. Single cell qPCR of thirty
classifier genes in 167 additional cells from MGH26 and MGH30 (Fig. S21) confirmed the
presence of multiple subtypes within these tumors in proportions similar to those identified
by single cell RNA-seq. Thus, while population level data detects the dominant
transcriptional program, it does not capture the true diversity of transcriptional subtypes
within a tumor.
Intratumoral subtype heterogeneity provides potentially important insights into tumor
biology. The stemness signature is strongest in individual cells conforming to the proneural
(r = 0.12–0.68, p<0.01, t-test) and classical (r= 0.26–0.64, p<0.01, t-test) subtypes, but
underrepresented in cells of the mesenchymal subtype (Figs. 3C,S22), which has been
correlated with astrocytic differentiation (21). In contrast, cells of the neural subtype do not
correspond to either in vitro model (Fig. 3C), but are more similar to normal
oligodendrocytes (Fig. 4B). These findings highlight parallels between intratumoral cellular
heterogeneity in glioblastoma and cellular diversity in the developing brain, with respective
subsets of tumor cells resembling a progenitor compartment, an astrocytic lineage, or an
oligodendrocytic lineage. This analysis also revealed “hybrid” states in which a single cell
scored highly for two subtypes, most commonly classical and proneural (progenitor states)
or mesenchymal and neural (differentiated states). These hybrid states may reflect aberrant
developmental programs and/or interconversion between phenotypic states.
Finally, we examined whether subtype heterogeneity is relevant to prognosis (24). We
focused on tumors classified as proneural, controlling for IDH1 status (3, 44) and binning
them into three groups: pure proneural tumors without any transcriptional signal for other
subtypes, low heterogeneity tumors with modest signal for other subtypes (defined as
average expression of the alternative subtype genes >50% of the median value in the group),
and high heterogeneity tumors with stronger signals for other subtypes (defined as >85% of
the median value in the group). We also partitioned the proneural tumors according to the
other detected subtype. We found that increased heterogeneity was associated with
decreased survival (Fig. 4C,4D). This suggests that the clinical outcome of a proneural
glioblastoma is influenced by the proportion of tumor cells of alternate subtypes, and
emphasizes the clinical significance of intratumoral heterogeneity.
We have leveraged single cell transcriptomics to characterize heterogeneous gene
expression programs within five glioblastoma tumors, and interrelate their transcriptional,
functional and (to a limited extent) genetic diversity. These findings have fundamental
implications for cancer biology and therapeutic strategies, as signaling molecules relevant to
targeted therapy show cellto-cell variability in expression and isoform selection. Moreover,
in vivo tumor cells display a spectrum of stemness and differentiation states, variable
proliferative capacity, and variable expression of quiescence markers, all of which may
confound therapeutic strategies. While population-level methods for glioblastoma
classification have provided important prognostic insights, they do not recapitulate the
diversity of transcriptional programs present in an individual tumor. Our analysis reveals
that tumors contain multiple cell states with distinct transcriptional programs and provides
inferential evidence for dynamic transitions. A better understanding of the spectrum and
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dynamics of cellular states in glioblastoma is thus critical for establishing faithful models
and advancing therapeutic strategies that address the complexity of this disease.
Supplementary Material
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Figure 1. Intratumoral glioblastoma heterogeneity quantified by single cell RNA-seq
(A) Workflow depicts rapid dissociation and isolation of glioblastoma cells from primary
tumors for generating single cell and bulk RNA-seq profiles and deriving glioblastoma
culture models. (B) Clustering of copy number variation (CNV) profiles inferred from RNA-
seq data for all single cells and a normal brain sample. Clusters (dendrogram) primarily
reflect tumor-specific CNV (colored bar coded as in panel D). Topmost cluster (red, arrow)
contains the normal brain sample and 10 single cells, nine of which correlate with normal
oligodendrocyte expression profiles and one with normal monocytes (‘Oligo’ and ‘Mono’,
black and white heatmap). (C) Heatmap of CNV signal normalized against the ‘normal’
cluster defined in (B) shows CNV changes by chromosome (columns) for individual cells
(rows). All cells outside the normal cluster exhibit chromosome 7 gain (red) and
chromosome 10 loss (blue), which are characteristic of glioblastoma. (D) Multidimensional
scaling illustrates the relative similarity between all 430 single cells and population controls.
The distance between any two cells reflects the similarity of their expression profiles. Cells
group by tumor (color code), but each tumor also contains outliers that are more similar to
cells in other tumors. (E) RNA-seq read densities (vertical scale of 10) over surface receptor
genes are depicted for individual cells (rows) from MGH30. Cell-to-cell variability suggests
a mosaic pattern of receptor expression, in contrast to constitutively expressed GAPDH.
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Figure 2. Unbiased analysis of intratumoral heterogeneity reveals coherent transcriptional
modules
(A) Gene sets that vary coherently between cells in specific tumors or across the global
dataset (colored boxes) were identified by principal component analysis or clustering (24).
Hierarchical clustering of these gene sets across all cells (tree) reveals four meta-signatures
related to hypoxia, complement/immune response, oligodendrocytes and cell cycle. (B)
Heatmap shows expression of the cell cycle meta-signature, selected cell cycle gene sets and
representative genes from the signature (rows) in individual glioblastoma cells (columns).
Cells were grouped by tumor and ordered by meta-signature score. (C) Heatmap depicts
hypoxia meta-signature as in (B).
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Figure 3. Transcriptional signatures of a stem-like compartment in primary glioblastoma
(A) Stem-like (GSC) and differentiated (DGC) culture models were derived from patient
tumor MGH26. GSCs grow as spheres (left, top), initiate tumors in xenotransplantation
(right, top), and express the stem cell marker CD133 (right, bottom). (B) Heatmap depicts
expression of genes (rows) from a stemness signature in differentiated models (DGC, left
columns), stem-like models (GSC, right columns) derived from 3 tumors, and in 70
individual cells from MGH31 (middle). (C) Bar plot depicts the Pearson correlation
coefficient (y-axis) between the stemness signature and selected transcriptional modules in
each tumor (colored bars): cell cycle, transcriptional targets of POU3F2, SOX2, SALL2,
OLIG2 (core TF) (43), NFI transcriptional targets (NFI) (42), and the proneural (PN),
classical (CL), mesenchymal (MES) and neural (N) subtypes defined by the Cancer Genome
Atlas (21). (D) Plot depicts stemness score (y-axis) computed from stemness signature gene
expression in individual cells from each tumor (xaxis) ordered by score. Bar plots depict the
overall variance (y-axis, standard deviation) in the stemness score (red) and the average
variance of simulated control gene sets (blue), confirming the significance of the gradient.
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Figure 4. Individual tumors contain a spectrum of glioblastoma subtypes and hybrid cellular
states
(A) Heatmap depicts average expression of classifier genes for each subtype (rows) across
all classifiable cells grouped by tumor (columns). PN: proneural, CL: classical, MES:
mesenchymal, N: neural. Each tumor contains a dominant subtype, but also has cells that
conform to alternate subtypes. (B) Hexagonal plots depict bootstrapped classifier scores for
all cells in each tumor. Each data point corresponds to a single cell and is positioned along
three axes according to its relative scores for the indicated subtypes (Supplemental
Methods). Cells corresponding to each subtype are indicated by solid color, while hybrid
cells are depicted by two colors. (C) Kaplan-Meier survival curves are shown for proneural
tumors from the Cancer Genome Atlas (21). Intratumoral heterogeneity was estimated based
on detected signal for alternative subtypes, and used to partition the tumors into a pure
proneural group and three groups with the indicated additional subtype. Tumors with
mesenchymal signal had significantly worse outcome than pure proneural (p<0.05). (D)
Kaplan-Meier survival curves shown for proneural tumors partitioned based on the relative
strength of alternative subtype signatures in aggregate (24). Tumors with high signal for
alternative subtypes had significantly worse outcome than pure proneural (p<0.05).
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